{"id":"NCT00811928","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)","officialTitle":"A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2008-12-19","resultsPosted":"2011-09-13","lastUpdate":"2017-04-07"},"enrollment":252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Leukopenia"],"interventions":[{"type":"DRUG","name":"Posaconazole","otherNames":["Noxafil","SCH 056592"]},{"type":"DRUG","name":"Fluconazole","otherNames":[]}],"arms":[{"label":"Posaconazole","type":"ACTIVE_COMPARATOR"},{"label":"Fluconazole","type":"ACTIVE_COMPARATOR"}],"summary":"A randomized, open label parallel controlled, multicenter study to evaluate safety and efficacy of Posaconazole oral suspension vs Fluconazole (capsule) in high-risk leukopenic patients for prevention of invasive fungal infection","primaryOutcome":{"measure":"Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period","timeFrame":"Up to 12 Weeks (84 days) plus 7 days","effectByArm":[{"arm":"Posaconazole","deltaMin":4,"sd":null},{"arm":"Fluconazole","deltaMin":11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23924680"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":124},"commonTop":["Pyrexia","Hepatic function abnormal","ENT disorder","Rash","Gingivitis"]}}